116 results about "Target drug" patented technology

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The application relates to the technical field of blood drug concentration detection, and discloses a blood drug concentration analysis method based on mass spectrometric detection, which comprises the following steps: adopting microfluidic technology in combination with solid-phase extraction to pretreat a blood sample to obtain a concentrated solution, so as to remove interfering components and concentrate target drug molecules; according to the physicochemical properties of the target drug molecules, the concentrated solution is selected to flow through a biosensor or is directly introduced into a chromatographic unit, and the target drug molecules in the liquid phase are converted into gas-phase ions when flowing through the biosensor; chromatography-mass spectrometry is adopted to detect the gas-phase ions or the concentrated solution, so as to obtain mass spectrum data; a machine learning model is used to analyze the spectrum data, to identify the drug types and calculate the concentration of the target drug molecules, and to generate an analysis report. The method is suitable for target drugs with different physicochemical properties, simplifies the detection process, and improves the applicability and accuracy of detection.

This invention relates to the field of animal model construction technology, and more particularly to a method for constructing an SMDT1 gene knockout animal model. The method utilizes gene editing technology to enable the animal model to... SMDT1 The sequence shown in SEQ ID No. 1 is missing from the locus. Stable and reliable results can be obtained using the construction method of this invention. SMDT1 Gene knockout animal models do not exhibit recombination repair and can be stably inherited, making them suitable for research. SMDT1 The biological functions of genes and MCU complexes, and their potential applications in... SMDT1 Gene-targeted drug development and guidance for livestock breeding have broad application prospects.

The application discloses a kind of bionic transmembrane protein affinity chromatography column and its preparation method and application.The system (iSTAC) realizes the in-situ construction of transmembrane protein in highly bionic dynamic microenvironment by integrating cell-free protein synthesis, functional mesoporous silica modification and amphiphilic (AH) peptide stabilized planar lipid bilayer technology.The core is to use long-chain PEG-24 crosslinking agent to retain lipid bilayer on the surface of silica gel, provide sufficient conformational dynamic space for multi-transmembrane protein, and introduce AH peptide to repair membrane defects, ensure that the receptor realizes directional embedding while maintaining natural functional attributes.The preparation cycle is shortened from 168 hours to 5 hours, which significantly improves the efficiency of targeted drug screening and in-situ analysis of binding sites.Using this platform, 5-HT 1A Receptor agonists crocin I and crocin II with anti-insomnia and neuroprotective effects are successfully screened from saffron, and the action site is accurately depicted.

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

This invention discloses a core-shell microneedle with both antibacterial and exudate-absorbing properties, and its preparation method, belonging to the field of microneedle drug delivery systems and acne treatment technology. The microneedle comprises: a core layer containing an exudate-absorbing component for absorbing exudate; and a shell layer covering the core layer, containing a microenvironment-responsive drug delivery unit and antibacterial nanoparticles loaded within the drug delivery unit. The drug delivery unit responds to the microenvironment of the acne lesion by releasing the antibacterial nanoparticles. This invention combines baicalein and surfactant into nanoparticles, loaded into a ROS-responsive shell layer formed by TSPBA and polyvinyl alcohol. Sodium polyglutamate is introduced into the core layer as an exudate-absorbing component. The core-shell microneedle is prepared by a two-step centrifugation method. This invention solves the problems of poor drug permeability, uncontrollable release, and exudate affecting treatment efficacy in traditional acne treatments. It achieves targeted drug release and exudate adsorption synergistic effects on acne lesions, improves drug bioavailability, reduces systemic side effects, and is suitable for the treatment of acne, especially inflammatory and purulent acne.

The application provides application of nucleolin as a drug target in preparation of a double-targeted treatment drug for colorectal cancer, and application of nucleolin as a double-targeted drug target in preparation of a drug for double-targeted killing of colorectal cancer tumor cells and tumor-related fibroblasts, the drug for double-targeted killing of colorectal cancer tumor cells and tumor-related fibroblasts, a pharmaceutical composition containing the drug and application thereof. The application uses nucleolin as a common drug target of colorectal cancer tumor cells and tumor-related fibroblasts, applies a double-targeted killing drug with nucleolin as a target, simultaneously kills colorectal cancer tumor cells and tumor-related fibroblasts, removes tumor cells while destroying tumor-related fibroblast-mediated tumor supporting microenvironment, and synergistically enhances the overall treatment effect of colorectal cancer.

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

A device may receive, by the computer system, a digital chemical structure for each of a plurality of ligand-drug conjugate compounds. A device may calculate by said one or more processors, an aggregation number for each of said plurality of ligand-drug conjugate compounds. A device may rank, by the computer system, at least a portion of said plurality of ligand-drug conjugate compounds based on said aggregation number. A device may identify, by the computer system, a plurality of low aggregation ligand-drug conjugate compounds based on said ranking, wherein said plurality of low aggregation ligand-drug conjugate compounds is a portion of said plurality of ligand-drug conjugate compounds having an aggregation number indicative of a predicted molecular aggregation lower than the predicted molecular aggregation of a remaining ligand-drug conjugate compounds within said plurality of ligand-drug conjugate compounds.

This invention provides a nanocomposite material with a core-shell structure. The nanocomposite material comprises: ZnO nanoparticles as the core; mesoporous silica as the shell coating the surface of the ZnO nanoparticles; an antibiotic loaded within the pores of the mesoporous silica; hyperbranched polylysine modified on the surface of the mesoporous silica; and a pH-responsive coating material as the outermost layer. The nanocomposite material provided by this invention enables precise targeted drug release in the colon, simultaneously addressing multiple factors leading to CDI recurrence, such as biofilm protection, spore storage, microbial disruption, and mucosal damage, through a sequential synergistic mechanism of "membrane disruption-bactericidal-spore inhibition-repair," thereby improving treatment efficacy.

This invention discloses a dosage analysis method for anesthetic drugs during surgery in patients with hypertension, hyperlipidemia, and hyperglycemia. This method integrates multi-source heterogeneous health data from the patient over the past five years to construct a personalized, structured health record. During anesthesia induction, based on the patient's individualized pharmacokinetic model and assessed drug interaction risks, it calculates and recommends precisely adjusted induction doses. During anesthesia maintenance, it innovatively decodes specific EEG signals to establish a dynamic mapping relationship between neurophysiological characteristics and pharmacokinetics. Based on EEG characteristics reflecting drug sensitivity and pain perception, it automatically and in real-time adjusts the predicted concentration of the target drug, achieving closed-loop precise control based on direct feedback from the central nervous system. The system automatically identifies all medications used by the patient, generates a drug interaction risk assessment report using a massive knowledge base, and dynamically updates the risk level and sends warnings during surgery based on real-time vital signs.

This invention discloses a drug-target interaction prediction method based on graph neural networks, belonging to the field of bioinformatics. It addresses the problem of inaccurate interaction prediction by acquiring molecular structure data of the target drug and target data of the target target; constructing a molecular neural network graph of the target drug and a target neural network graph of the target target, obtaining atomic node vectors, atomic edge vectors, target node vectors, and target edge vectors; constructing molecular feature vectors of the target drug and target feature vectors of the target target, thereby obtaining a drug-target interaction prediction matrix; setting positive and negative samples and training using a multilayer perceptron network model to obtain a drug-target interaction prediction model; and using the drug-target interaction prediction model to identify the target drug and target target, determining the interaction between them. This invention achieves accurate prediction of the interaction between the target drug and target target.

The application provides a cell-targeting drug primary screening model training method, a drug primary screening method and equipment. The method comprises the following steps: obtaining molecular fingerprint feature data corresponding to each compound sample with label information to form a corresponding original data set, performing data screening on the original data set by using a distance measurement method, and training a regression model based on a graph neural network to learn the structure topology of each compound sample. The model is trained as a cell-targeting drug primary screening model for predicting whether a compound has potential cell-targeting drug activity. The application can effectively improve the comprehensiveness of molecular representation during the training process of the cell-targeting drug primary screening model, effectively improve the generalization ability of the cell-targeting drug primary screening model obtained by training, effectively improve the applicability of the cell-targeting drug primary screening model obtained by training, and improve the accuracy and reliability of the prediction result of the potential cell-targeting drug activity predicted by the model.

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

This invention belongs to the field of biomedical technology and discloses the application of Rab30 as a target and its activator in the preparation of drugs for the prevention or treatment of metabolic dysfunction-related fatty liver disease (MASLD). This invention reveals for the first time that Rab30 plays a crucial role in lipid clearance and protection in the pathological process of MASLD by mediating lipophage and fatty acid oxidation pathways. It also confirms that the small molecule compound curculigoside A can serve as a targeted activator of Rab30. In vitro and in vivo experiments show that curculigoside A can directly bind to the Rab30 protein and significantly enhance its stability, thereby specifically and dependently targeting Rab30 to effectively improve lipid overload in the liver under pathological stress and inhibit the associated inflammation and fibrosis. This invention provides a clear therapeutic target and targeted drug candidate for the prevention and treatment of MASLD, and has significant clinical translational value.

The present application relates to the technical field of drug quality detection, and particularly relates to a rapid detection method for organic solvent residues in drugs. By collecting organic solvent residue parameter information of target drugs in a historical period, a comprehensive score benchmark containing the types and concentration weighted fusion is determined; based on the comprehensive score and statistical determination, the stability risk of a gas chromatography device is determined; if there is a risk, the first and second heating rates of the chromatography effluent are extracted, and the effectiveness of the chromatography effluent of the target drug is determined in combination with the peak shape index output by the hydrogen flame ionization detector; the heating rate direction and value are adjusted respectively for different peak shape abnormalities. The present application realizes active monitoring of device stability and self-adaptive correction of the heating rate, and overcomes the problem of low detection accuracy of organic solvent residues in drugs.

This invention provides hepatocellular carcinoma-derived growth factor (HDGF) as a target for resistance to tyrosine kinase inhibitors and its related applications. This invention provides the application of HDGF as a target in screening and / or preparing drugs that can improve resistance to tyrosine kinase inhibitors in patients. This invention discovers that high expression of HDGF is one of the mechanisms of resistance to molecularly targeted drugs such as gefitinib and other tyrosine kinase inhibitors. Targeting HDGF can effectively improve resistance to gefitinib in NSCLC and enhance therapeutic efficacy.

This application relates to the field of computer science and discloses a method, device, medium, and product for simulating clinical trials based on molecular perturbation spectra. The method includes: determining the molecular perturbation spectrum of a target drug; determining a predictive model from genomics to high-dimensional omics based on genomic and high-dimensional omics data in a first population dataset; determining the predicted omics data for an individual based on the predictive model and the genomic data of an individual in a second population dataset; wherein the second population dataset also includes clinical outcome data; determining a grouping scheme for the simulated clinical trial by optimizing an individual allocation model based on the molecular perturbation spectrum and the predicted omics data of all individuals, maximizing the similarity between the predicted omics differences and the molecular perturbation spectrum between the simulated experimental group and the simulated control group; constructing a simulated clinical trial based on the grouping scheme; and determining an estimated value of the intervention effect of the target drug based on the differences in clinical outcomes between the simulated experimental group and the simulated control group in the simulated clinical trial.

The application relates to application of PUS1 in improving sensitivity of enzalutamide to prostate cancer treatment. Through bioinformatics analysis and a series of in-vivo and in-vitro experiments, the application first discovers and determines the key role of the expression level of PUS1 in reducing the sensitivity of enzalutamide in treating prostate cancer, and deeply studies the mechanism, and determines that the PUS1 promotes enzalutamide resistance of prostate cancer in dependence on the Psi modification activity. The application enriches the related mechanism of drug resistance generation and regulation in the process of enzalutamide in treating prostate cancer, provides sufficient scientific basis and theoretical basis for exploring new prostate cancer diagnosis, prognosis judgment and treatment molecular target, and developing new targeted drugs, and has important social value and scientific significance.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

The application discloses anti-human ROR1 antibodies, genes and application thereof, and a heavy chain variable region and a light chain variable region of the anti-human ROR1 antibodies, which are shown as SEQ ID NO. 1-17. Anti-human ROR1 antibodies in some examples of the application can be combined with the extracellular region of ROR1 with high efficiency and specificity, and the affinity is as high as 1.329 nM, and the anti-human ROR1 antibodies can be used for preparing detection reagents and targeted drugs.

The application provides a kind of targeting drug-loaded liposome combined functional hydrogel and its preparation method and application, including active targeting liposome and functional gelatin hydrogel, make the active targeting liposome disperse in functional gelatin hydrogel, under the photo initiator, ultraviolet crosslinking solidification obtains the targeting drug-loaded liposome combined functional hydrogel;The functional gelatin hydrogel includes methacrylic anhydride grafting gelatin hydrogel and gallic acid grafting gelatin hydrogel, and the active targeting liposome is RGD peptide modified drug-loaded liposome.The application overcomes the defects of poor targeting, large systemic toxic side effects and insufficient regulation of joint immune microenvironment in the existing methotrexate single drug therapy for rheumatoid arthritis.

The application relates to application of siRNA-OTUB1 in preparation of drugs for preventing or treating myocardial cell hypertrophy, and belongs to the biomedical technical field.The nucleotide sequence of the OTUB1 gene is shown as SEQ ID NO.1, and the targeted nucleotide sequence of the siRNA-OTUB1 for specifically interfering with the expression of the OTUB1 gene is shown as SEQ ID NO.2 or SEQ ID NO.3.The application innovatively proposes a strategy for preventing or treating myocardial cell hypertrophy by taking deubiquitinase OTUB1 as a core target point and by interfering with the expression thereof.In a myocardial cell experiment of a milk rat, the application of the designed siRNA-OTUB1 can effectively reduce the expression levels of OTUB1 mRNA and OTUB1 protein, and further reduce the degree of myocardial cell hypertrophy.Based on the finding, the OTUB1 gene can be developed as a novel treatment target point for myocardial cell hypertrophy, is used for designing a targeted drug, and provides a new technical thought for precise treatment of myocardial hypertrophy.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

This invention discloses a pulsed electric field ablation electrode with an integrated triggerable embedded drug ring, relating to the field of medical device technology. The electrode includes a 3D-printed embedded drug ring, an electrode substrate, an electrode tip, and an annular groove. The electrode tip is located at the end of the electrode substrate and has an annular groove. The 3D-printed embedded drug ring carries an antitumor drug, is fixed to the annular groove, and its outer surface forms a smooth and continuous working surface with the electrode substrate. This invention can simultaneously achieve targeted drug release when a high-voltage pulsed electric field is applied for ablation, integrating pulsed electric field ablation with local drug delivery functions. This solves the problem of the single function of traditional electrodes. In scenarios such as percutaneous or open ablation of liver cancer and endoscopic ultrasound ablation of pancreatic cancer, it can achieve precise synergy between physical ablation and chemotherapy / immunotherapy, effectively improving the tumor treatment effect.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

The present application relates to the technical field of targeted drug matching, and particularly relates to a qi deficiency and dampness accumulation type constipation targeted drug matching method and system and a storage medium, which comprises the following steps: collecting patient related characteristic data, calculating the activation degree score of each traditional Chinese medicine target point of the patient based on a preset three-level traditional Chinese medicine target point system, and determining the qi deficiency weight and dampness accumulation weight of the patient; according to the activation degree score, mapping the priority weight of the corresponding molecular target point through the preset mapping relationship between the traditional Chinese medicine target point and the molecular target point bidirectional binding, obtaining the double target point priority matrix of the patient; based on the double target point priority matrix, setting the weighting coefficient of each target point with the qi deficiency weight and the dampness accumulation weight, calculating the double target point matching degree of the simultaneous matching of the traditional Chinese medicine target point and the molecular target point in the drugs and drug combinations of the qi deficiency and dampness accumulation type constipation prescription, and generating a drug use scheme. The present application realizes the synergistic matching of the traditional Chinese medicine and western medicine double target points of the qi deficiency and dampness accumulation type constipation, improves the drug precision and clinical curative effect, and reduces the side effects and recurrence rate.

The application discloses application of an S1PR1 selective agonist SAR247799 in preparation of a drug for treating neuromyelitis optica spectrum disorders. The SAR247799 can up-regulate S1PR1 expression of astrocytes, activate an S1PR1 signal path of the astrocytes, inhibit AQP4-IgG and complement-mediated damage of the astrocytes, reduce loss of AQP4, GFAP and ALDH1L1 in a lesion area of brain tissue of a neuromyelitis optica spectrum disorder model mouse, and relieve pathological damage of the neuromyelitis optica spectrum disorder model. In-vivo and in-vitro experiments prove that the SAR247799 can effectively inhibit AQP4-IgG and complement-dependent cytotoxicity effects and promote survival of the astrocytes. The application provides a novel, efficient and specific targeted drug for clinical treatment of the neuromyelitis optica spectrum disorder.